相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Resveratrol-modified mesoporous silica nanoparticle for tumor-targeted therapy of gastric cancer
Mingzhen Lin et al.
BIOENGINEERED (2021)
Cancer nanomedicine: progress, challenges and opportunities
Jinjun Shi et al.
NATURE REVIEWS CANCER (2017)
Engineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective
Javed Ahmad et al.
CURRENT PHARMACEUTICAL DESIGN (2016)
Cancer active targeting by nanoparticles: a comprehensive review of literature
Remon Bazak et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Ultra-High Throughput Synthesis of Nanoparticles with Homogeneous Size Distribution Using a Coaxial Turbulent Jet Mixer
Jong-Min Lim et al.
ACS NANO (2014)
Nanoparticles for Combination Drug Therapy
Liang Ma et al.
ACS NANO (2013)
Microfluidic Platform for Combinatorial Synthesis and Optimization of Targeted Nanoparticles for Cancer Therapy
Pedro M. Valencia et al.
ACS NANO (2013)
Nanomedicines as Cancer Therapeutics: Current Status
Sohail Akhter et al.
CURRENT CANCER DRUG TARGETS (2013)
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies
Glen J. Weiss et al.
INVESTIGATIONAL NEW DRUGS (2013)
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Michael L. Etheridge et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2013)
Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug
Xiaoyang Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Population Pharmacokinetics of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
Huali Wu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Twan Lammers et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery
Shrirang Karve et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Is It Time for a Metagenomic Basis of Therapeutics?
Henry J. Haiser et al.
SCIENCE (2012)
Treating metastatic cancer with nanotechnology
Avi Schroeder et al.
NATURE REVIEWS CANCER (2012)
The clinical development of inhibitors of poly(ADP-ribose) polymerase
H. Calvert et al.
ANNALS OF ONCOLOGY (2011)
Clinical trials in the era of personalized oncology
Michael L. Maitland et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge
Rochelle R. Arvizo et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2011)
Increased methylation variation in epigenetic domains across cancer types
Kasper Daniel Hansen et al.
NATURE GENETICS (2011)
The Complex Role of Multivalency in Nanoparticles Targeting the Transferrin Receptor for Cancer Therapies
Jin Wang et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive Nanovalves
Huan Meng et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Targeting of αvβ3-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles
Walter J. Akers et al.
NANOMEDICINE (2010)
Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
Chung Hang J. Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy
Jason Doles et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Lipid Nanomedicines for Anticancer Drug Therapy
Ander Estella-Hermoso de Mendoza et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2009)
Matrix-insensitive protein assays push the limits of biosensors in medicine
Richard S. Gaster et al.
NATURE MEDICINE (2009)
Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates
Andrzej Myc et al.
ANTI-CANCER DRUGS (2008)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
Seven challenges for nanomedicine
Wendy R. Sanhai et al.
NATURE NANOTECHNOLOGY (2008)
An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin
Alberto Gabizon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Clinical pharmacology of liposomal anthracyclines: Focus on pegylated liposomal doxorubicin
Rebecca Solomon et al.
CLINICAL LYMPHOMA & MYELOMA (2008)
Immunological properties of engineered nanomaterials
Marina A. Dobrovolskaia et al.
NATURE NANOTECHNOLOGY (2007)
Micellar nanocarriers: Pharmaceutical perspectives
V. P. Torchilin
PHARMACEUTICAL RESEARCH (2007)
Acute toxicological effects of copper nanoparticles in vivo
Z Chen et al.
TOXICOLOGY LETTERS (2006)
EphA2 as a target for ovarian cancer therapy
CN Landen et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Epigenetic differences arise during the lifetime of monozygotic twins
MF Fraga et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Nanomedicine: current status and future prospects
SM Moghimi et al.
FASEB JOURNAL (2005)
Folate receptor targeted biodegradable polymeric doxorubicin micelles
HS Yoo et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077B103) in a preclinical tumor model of melanoma
WC Zamboni et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
NJ Robert et al.
SEMINARS IN ONCOLOGY (2004)
Liposomal anthracycline treatment for ovarian cancer
M Markman et al.
SEMINARS IN ONCOLOGY (2004)
Use of liposomal anthracyclines in Kaposi's sarcoma
SE Krown et al.
SEMINARS IN ONCOLOGY (2004)
Effect of pegylation on pharmaceuticals
JM Harris et al.
NATURE REVIEWS DRUG DISCOVERY (2003)
Modelling the molecular circuitry of cancer
WC Hahn et al.
NATURE REVIEWS CANCER (2002)
Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy
AA Gabizon
CANCER INVESTIGATION (2001)
'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG):: influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption
R Gref et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2000)
分享论文
